LQDA NASDAQ
Morrisville, NC 27560
US
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bloch Stephen M | S-Sale | 96,400 | $89.44 | 2026-07-23 |
| Bloch Stephen M | S-Sale | 3,600 | $90.71 | 2026-07-23 |
| Bloch Stephen M | S-Sale | 37,406 | $87.70 | 2026-07-22 |
| Bloch Stephen M | S-Sale | 48,032 | $88.65 | 2026-07-22 |
| Bloch Stephen M | S-Sale | 14,562 | $89.24 | 2026-07-22 |